Developing medicines that deliver alpha-particle radiation to cancer cells
Radiation therapy can damage healthy cells as well as cancer cells, causing side effects that vary with the treatment area and dose. Some effects continue after treatment ends, while others appear months or years later and can be long-lasting or permanent.
AIGA Therapeutics is developing medicines that target cancer cells with alpha-particle radiation. Its approach combines targeted treatment with diagnostic imaging intended to help select patients and monitor their response to treatment.
What stands out about AIGA Therapeutics
FACIT lists AIGA Therapeutics among recently funded Prospects recipients at pre-seed stage; the programme provides grant-like funding.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.